CD44v6 overexpression related to metastasis and poor prognosis of colorectal cancer: A meta-analysis

Q2 Medicine Oncotarget Pub Date : 2016-12-24 DOI:10.18632/oncotarget.14163

Jilin Wang, Wenyu Su, Yan-wei Lin, H. Xiong, Yingxuan Chen, Jie Xu, J. Fang

{"title":"CD44v6 overexpression related to metastasis and poor prognosis of colorectal cancer: A meta-analysis","authors":"Jilin Wang, Wenyu Su, Yan-wei Lin, H. Xiong, Yingxuan Chen, Jie Xu, J. Fang","doi":"10.18632/oncotarget.14163","DOIUrl":null,"url":null,"abstract":"CD44v6 has recently been reported as a biomarker for colorectal cancer. However, the clinical and prognostic significance of CD44v6 in colorectal cancer remains controversial. Therefore, we performed a meta-analysis to clarify this issue. A comprehensive literature search was performed using Medline, Embase and Web of Science, and the statistical analysis was conducted using Stata software. A total of twenty-one studies including 3918 colorectal cancer cases were included. The pooled analysis showed that CD44v6 overexpression in colorectal cancer was an independent prognostic marker correlating with lower 5-year overall survival rate (OR=0.78, 95%CI =0.67-0.91, p=0.001). CD44v6 overexpression was also associated with more lymph node invasion (OR=1.48, 95%CI= 1.02-2.15, p=0.04), and advanced Dukes stage (OR=2.47, 95%CI= 1.29-4.73, p=0.01). In addition, while excluding Zolbec's study, CD44v6 overexpression was associated with distance metastasis (OR=1.65, 95%CI =1.13-2.40, p=0.01). Taken together, this meta-analysis suggested that CD44v6 is an efficient prognostic factor in colorectal cancer.","PeriodicalId":19499,"journal":{"name":"Oncotarget","volume":"8 1","pages":"12866 - 12876"},"PeriodicalIF":0.0000,"publicationDate":"2016-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"23","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncotarget","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18632/oncotarget.14163","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 23

Abstract

CD44v6 has recently been reported as a biomarker for colorectal cancer. However, the clinical and prognostic significance of CD44v6 in colorectal cancer remains controversial. Therefore, we performed a meta-analysis to clarify this issue. A comprehensive literature search was performed using Medline, Embase and Web of Science, and the statistical analysis was conducted using Stata software. A total of twenty-one studies including 3918 colorectal cancer cases were included. The pooled analysis showed that CD44v6 overexpression in colorectal cancer was an independent prognostic marker correlating with lower 5-year overall survival rate (OR=0.78, 95%CI =0.67-0.91, p=0.001). CD44v6 overexpression was also associated with more lymph node invasion (OR=1.48, 95%CI= 1.02-2.15, p=0.04), and advanced Dukes stage (OR=2.47, 95%CI= 1.29-4.73, p=0.01). In addition, while excluding Zolbec's study, CD44v6 overexpression was associated with distance metastasis (OR=1.65, 95%CI =1.13-2.40, p=0.01). Taken together, this meta-analysis suggested that CD44v6 is an efficient prognostic factor in colorectal cancer.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

CD44v6过表达与结直肠癌转移及不良预后相关的meta分析

CD44v6最近被报道为结直肠癌的生物标志物。然而，CD44v6在结直肠癌中的临床和预后意义仍存在争议。因此，我们进行了荟萃分析来澄清这一问题。采用Medline、Embase和Web of Science进行全面的文献检索，并采用Stata软件进行统计分析。共纳入21项研究，包括3918例结直肠癌病例。合并分析显示，CD44v6在结直肠癌中过表达是与较低的5年总生存率相关的独立预后标志物(OR=0.78, 95%CI =0.67-0.91, p=0.001)。CD44v6过表达还与淋巴结侵袭较多(OR=1.48, 95%CI= 1.02-2.15, p=0.04)和Dukes分期晚期(OR=2.47, 95%CI= 1.29-4.73, p=0.01)相关。此外，在排除Zolbec的研究后，CD44v6过表达与远处转移相关(OR=1.65, 95%CI =1.13-2.40, p=0.01)。综上所述，该荟萃分析表明CD44v6是结直肠癌的有效预后因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊